OralAllergic conditionsAdult: For symptomatic relief of seasonal and perennial allergic rhinitis; chronic idiopathic urticaria: 10 mg once daily. Child: 6-12 years 5 mg bid; >12 years Same as adult dose. Treatment and dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Renal impairment: | CrCl (ml/min) | Dosage Recommendation | | <10 | Contraindicated. | | <30 | 5 mg once every 2 days. | | 30-49 | 5 mg once daily. | | 50-79 | Same as adult dose. |
Intravenous
Acute urticaria
Adult: 10 mg 24 hourly over 1-2 minutes.
Child: 6 months to 5 years 2.5 mg 24 hourly; 6-11 years 5-10 mg 24 hourly, depending on the severity of symptoms; ≥12 years Same as adult dose.
Ophthalmic
Ocular itching associated with allergic conjunctivitis
Adult: Instil 1 drop into the affected eye(s) bid (approx 8 hours apart).
Child: ≥2 years Same as adult dose.
|
May be taken with or without food.
|
|
|
Patients with epilepsy and patients at risk of convulsions; risk factors for urinary retention (e.g. spinal cord lesion, prostatic hyperplasia). Hepatic and mild to moderate renal impairment. Children, elderly. Pregnancy and lactation. Patient Counselling This drug may cause CNS depression (e.g. somnolence), if affected, do not drive or operate machinery. Remove contact lenses prior to admin of cetirizine ophthalmic solution, wait 10 minutes before reinserting. Monitoring Parameters Monitor relief of symptoms, sedation, mental alertness, and anticholinergic effects.
|
Eye disorders: Decreased visual acuity, ocular hyperaemia (ophth soln).
Gastrointestinal disorders: Abdominal pain, dry mouth, nausea, diarrhoea, vomiting.
General disorders and administration site conditions: Fatigue, local pain at instillation site (ophth).
Nervous system disorders: Dizziness, headache, somnolence.
Respiratory, thoracic and mediastinal disorders: Pharyngitis, rhinitis, epistaxis, bronchospasm.
|
Symptoms: Confusion, diarrhoea, dizziness, fatigue, headache, malaise, mydriasis, pruritus, restlessness, sedation, somnolence, stupor, tachycardia, tremor, and urinary retention. Management: Symptomatic and supportive treatment. Gastric lavage may be performed following early ingestion.
|
Additive CNS depression when administered concomitantly with other CNS depressants.
|
Decreased rate of absorption with food. Enhanced CNS depressant effect with alcohol.
|
May cause false-positive serum TCA screen. May suppress the wheal and flare reactions to skin test antigens.
|
Cetirizine, a piperazine derivative and metabolite of hydroxyzine, is an antihistamine which competitively and selectively inhibits H1 receptors in the gastrointestinal tract, blood vessels, and respiratory tract.
Onset: Suppression of skin wheal and flare: 20-60 minutes.
Duration: Suppression of skin wheal and flare: ≥24 hours.
Absorption: Rapidly absorbed from the gastrointestinal tract. Decreased rate of absorption with food. Time to peak plasma concentration: Approx 1 hour.
Distribution: Enters breast milk. Volume of distribution: 0.56 L/kg. Plasma protein binding: 93%.
Metabolism: Metabolised limitedly in the liver.
Excretion: Mainly via urine (50% as unchanged drug); faeces (10%). Elimination half-life: 8 hours.
|
Intravenous: Store below 25°C. Ophthalmic: Store below 25°C. Oral: Store below 25°C.
|
|
|
S01GX12 - cetirizine ; Belongs to the class of other ophthalmologic antiallergics.
R06AE07 - cetirizine ; Belongs to the class of piperazine derivatives used as systemic antihistamines.
|
Sign Out
